Industry news

Drug Name Development: Regulatory Changes You Need to Know

FiercePharma

Small changes in regulatory guidance can translate to big risks if you’re not adjusting your strategy and timelines proactively. A delay as short as six months in a pharmaceutical product launch can result in an average loss of $100 million.

Survey Measures Biopharma Career Highs and Lows

Rita C. Peters / BioPharm International

Complex biologic drugs, including personalized medicines, demand more sophisticated formulation and manufacturing methods, as well as talented, experienced pharmaceutical scientists and engineers to deliver therapies to patients. Advanced technology for manufacturing is expected to increase the required skill sets of biopharma workers.

U.K. biopharma deal meant to defy Brexit skeptics has fizzled

Nick Paul Taylor / FierceBiotech

The United Kingdom government has unveiled its highly anticipated deal with the life sciences sector. As previously leaked, the document details planned investments from drug developers including GlaxoSmithKline, although many of the commitments are vague or already known.

Researchers in Tomsk developed a new medicine to regulate blood pressure

GMP News

The scientists at the Siberian State Medical University (SSMU) in Tomsk have developed a long-acting drug that regulates the blood pressure. The medicine does not require frequent administration and acts only when the blood pressure is really high.

Pfizer’s Medivation breast cancer PARP boosts PFS in phase 3

Ben Adams / FierceBiotech

An experimental PARP med bought up as part of Pfizer’s multibillion-dollar Medivation buyout performed well in a late-stage trial as the Big Pharma eyes regulatory filings.

Social listening data is good, but it's better when combined with offline insights: agency

Beth Snyder Bulik / FiercePharma

Social listening can be a powerful tool for pharma companies. The good news is that most pharma companies are now using it to tap into online conversations and unearth data and intel. What would make it even more effective, however, is marrying that online social listening data with offline intelligence, says the director of social media at CMI/Compas.

08 December 2017

Russian demand for pharma products outweighs isolationist policy

Dan Stanton / In-Pharma Technologist.com

Protectionist measures introduced in 2011 looked to increase local drug manufacture and reduce reliance on imports have led to a number of Big Pharma forming collaborations with domestic drugmakers in order to tap the market opportunities. Pfizer, for example, teamed with Russian pharma firm NovaMedica in May to build an aseptic manufacturing plant in Kaluga.

Russian government elaborated a mechanism for drug labeling support

GMP News

The Russian Ministry of Industry and Trade published the Rules for providing the federal subsidies to the Russian Foundation for Technological Development, a federal state autonomous institution, for the projects to implement the labeling of medicinal products in the pharmaceutical industry.

Pharma 2020 program supported more than 400 drug development projects

GMP News

Speaking at the 8th All-Russian Congress of Patients, Sergey Tsyb, the Deputy Minister of Industry and Trade of the Russian Federation, noted the constructive dialog between the Ministry of Industry and Trade, Russian Union of Patients and patient organizations in the country.

Russian pharma companies are registering medicines in more than 60 countries

GMP News

When Pharma-2020, a federal program, was launched in 2010, its first priority was to provide domestically manufactured medicines, that are affordable in terms of price and acceptable in terms of quality to Russian patients, including the analogs of the most effective foreign drugs. But, at the same time, the Russian Ministry of Industry and Trade announced that the strategic goal was to develop the innovative medicinal products in Russia and bring them to international markets.